67.66 <%= Resources.Global.txtDown %>
Updated 22/08/2019
Change % -0.06% Stock price decreasing
Change -0.04 Stock price decreasing
Volume 360,698
High 68.16
Low 67.26
Open 67.80
ISIN BE0003739530
Prev close 67.70
# of shares 194.51M
Market cap 13,160M EUR

Market closed
Market is closed, opens at 08:00
Price development Latest 1 week 1 month 3 months 6 months 1 year
  67.66 -1.1% Stock price decreasing -9.9% Stock price decreasing -2.4% Stock price decreasing -13.1% Stock price decreasing -14.6% Stock price decreasing
Powered by TradingView

Company profile

UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, both of which have lost patent protection. The firm's newer drugs include Cimzia (rheumatoid arthritis, psoriatic arthritis, and Crohn's disease), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), and Briviact (epilepsy).

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
24 August 2019 10:55:16
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190819.1 - EUROWEB4 - 2019-08-24 11:55:16 - 2019-08-24 10:55:16 - 1000 - Website: OKAY